ERBB2 and cancer: We found that most PIK3CA hotspot mutations (H1047R/L, E542K, E545K and N345K) were shown to suppress the proliferation of HER2+ cancer cells (Figure 3B left upper panel and Table S6), while these mutations exhibited a higher tolerance to lapatinib treatment (Figure 3B left down panel and Table S7).